ALK and non-small cell lung carcinoma: Based on these results, tiragolumab in combination with atezolizumab was granted breakthrough therapy designation (BTD) by the FDA in 2021 as first-line treatment of metastatic PD-L1-high NSCLC patients without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations [31].